Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options. Non-muscle-invasive bladder cancer remains a ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

From pregnancy to menopause, bladder incontinence affects women of all ages, but a Belfast experts say it’s no longer ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...

Patients with early bladder cancer who have gone 5 years without relapse may be considered “cured,” researchers suggested. In considering outcomes for evaluating how “cure” is defined in early bladder ...